Science Corp develops visual prosthetic technologies designed to restore vision through optogenetic stimulation of retinal neurons. The company’s approach focuses on interfacing directly with the visual system to bypass damaged photoreceptors. Its platform combines genetic, optical, and electronic components to enable patterned neural stimulation. Science Corp positions its work within regulated clinical and therapeutic development contexts.

The technology uses optogenetics to render retinal neurons responsive to light, followed by stimulation with microLED arrays that deliver precisely patterned optical signals. These patterns are designed to encode visual information in a way that downstream visual pathways can interpret. By controlling light delivery at high spatial and temporal resolution, the system aims to recreate functional visual input. This approach avoids traditional electrode-based stimulation in favor of optical neural activation.

Science Corp targets patients with severe vision loss caused by retinal degenerative diseases. The platform is intended for use within specialized clinical settings and clinical trials rather than consumer deployment. Its positioning reflects broader efforts to combine gene therapy and advanced hardware to restore sensory function through direct neural interfacing.